Compare ResMed Inc. (RMD) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Sunrun Inc — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while Sunrun Inc trades at $11.5 (market cap $2.73B). The key difference: ResMed Inc. is far larger — about 10.6× Sunrun Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| RMD | RUN | |
|---|---|---|
Market Cap | $28.81B | $2.73B |
Sector | Health | Technology |
52-Week High | $293.73 | $21.41 |
52-Week Low | $182.82 | $9.07 |
Enterprise Value | $27.99B | $16.92B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Sunrun (RUN) trades at $11.44, down 3.46% today, with a bearish technical outlook despite strong recent earnings beats. The company shows solid fundamentals with a 17.88% net income margin and attractive valuation ratios (P/E 5.37, P/B 0.82). Recent developments include a major virtual power plant partnership with Tesla and Renew Home, expanding grid capacity to 425 megawatts.
While analyst consensus remains bullish with a $15.91 price target, negative cash flows and high debt-to-asset ratio (70.76%) present significant risks. The stock offers value potential if execution improves, but investors face volatility from operational challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
